Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
Status:
Recruiting
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK)
of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety,
tolerability, PK and efficacy of multiple doses of ARO-ENaC in patients with pulmonary cystic
fibrosis.